Answers are grounded in this paper and cite their sources.
Alchemical transformations, whereby chemical species are modified seamlessly, represent a powerful tool in molecular simulations and free-energy calculations, with a broad range of applications. A general-extent, or alchemical parameter, λ ∈ [0,1], describes the gradual transition between the initial and final states of the transformation, and its discretization critically affects the reliability and efficiency of the free-energy calculations. For transformations involving large moieties, free-energy perturbation (FEP) and thermodynamic integration (TI) require numerous intermediates, or λ-states, to ensure appropriate overlap of the configurational ensembles and suitable convergence of the simulation, each state demanding extensive sampling, which burdens computational feasibility. To address this limitation, we combine λ-dynamics─treating λ as a dynamic variable─with the enhanced-sampling approach well-tempered metadynamics-extended adaptive biasing force (WTM-eABF), forming the basis of WTM-λABF. By handling λ as a continuously varying collective variable (CV) and applying a bin-discretized bias, WTM-λABF efficiently explores the λ-space, even when the latter is stratified in numerous intermediates. Calculations of free-energies of hydration, of protein-ligand binding, and of amino-acid mutations in proteins reveal that WTM-λABF consistently converges faster than standard FEP or λ-ABF, with its advantages becoming more pronounced as the number of intermediates rises. We find that WTM-λABF can handle alchemical transformations efficiently with as many as 1,000 intermediates, allowing transformations involving large moieties, or significant potential-energy changes, to be tackled with utmost accuracy. Additionally, its rapid exploration of the continuous λ-space accelerates sampling in the orthogonal space. We are confident that WTM-λABF has the potential to serve as a foundational method for routine applications relevant to chemistry and biophysics, ranging from drug discovery to protein engineering and design.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: